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erosclerotic lesions. T0901317, an LXR agonist, augmented protein kinase A (PKA)-induced mineral-
ization and alkaline phosphatase (ALP) activity in aortic smooth muscle cells isolated from wild-
type, but not from Lxrb/mice. A six-hour T0901317 treatment augmented the PKA-induced expres-
sion of the phosphate transporter Pit-1, a positive regulator of mineralization, suggesting a direct
role. A ten-day T0901317 treatment attenuated PKA-induced expression of mineralization inhibi-
tors, osteopontin and ectonucleotide pyrophosphatase/phosphodiesterase-1, suggesting an indirect
role. The effects of T0901317 were attenuated by inhibition of ALP, Pit-1 and Rho-associated kinase,
but not by inhibition of PKA. These results suggest that T0901317-augmented mineralization occurs
downstream of PKA, involving both direct and indirect LXR-mediated pathways.
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Liver X receptor (LXR), the nuclear hormone receptor, plays a
crucial role in cholesterol homeostasis. LXR activates expression
of genes involved in cholesterol efﬂux, such as ABCA1, and reduces
cytokine-induced gene expression [1,2]. In mice, synthetic LXR
agonists reduce atherosclerosis, while LXR deﬁcient hyperlipi-
demic mice have accelerated atherosclerosis [3–5]. LXRa is ex-
pressed primarily in the liver, intestines, adipose tissue, adrenal
glands, lungs, and kidneys, whereas LXRb is expressed ubiquitously
and is likely to mediate any direct effects on vascular cells. We and
others have found that oxysterols, now known to be physiological
ligands of LXR [6], stimulate matrix mineralization in vascular cells
[7,8]. However, the effect of synthetic LXR agonists on vascular cell
calciﬁcation is not known.
Vascular calciﬁcation, highly prevalent in atherosclerosis, as
well as in diabetes and chronic kidney disease [9], is increasingly
being used as a surrogate marker for atherosclerosis. Its presence
is associated with a poor prognosis, speciﬁcally a greater likelihood
of cardiovascular events such as myocardial infarction, stroke, and
death [10]. Vascular calciﬁcation is promoted bymonocyte–macro-
phages and inﬂammatory cytokines commonly present in athero-
sclerotic plaques [11–13].chemical Societies. Published by E
t).Under physiological conditions, vascular calciﬁcation is
constitutively suppressed by local factors in the extracellu-
lar milieu [14,15]. Extracellular pyrophosphate (PPi) is gener-
ated from cleavage of nucleotide triphosphates by ecto-
nucleotide pyrophosphatase/phosphodiesterase-1 (Enpp1/Npp1/
PC-1). Absence of this enzyme leads to a congenital, life-
threatening vascular calciﬁcation in humans [16]. Addition-
ally, in vitro studies showed that osteopontin (OPN), an extracel-
lular structural protein, also negatively regulates vascular
calciﬁcation [17]. In contrast, vascular calciﬁcation is stimulated
by increased phosphate levels and increased alkaline phospha-
tase (ALP) activity. High phosphate acts, at least in part, through
Pit-1, a type III sodium-dependent phosphate cotransporter
[18,19]. Terkeltaub and colleagues showed that the primary
in vivo role of ALP is to cleave the mineralization inhibitor, PPi
[20].
We previously established an in vitro model of PKA-induced
vascular cell calciﬁcation [21,22]. This model has a physiological
basis since PKA is a mediator of parathyroid hormone (PTH),
which when chronically elevated leads to aortic calciﬁcation in
rodent models [23] and is associated with increased atheroscle-
rotic calciﬁcation in patients with end-stage renal disease [24].
In the present study, we tested the effects of LXR agonists on
this in vitro PKA-induced calciﬁcation model in primary aortic
cells isolated from wild-type (WT) and Lxrb/ mice.lsevier B.V. All rights reserved.
Fig. 1. Liver X receptor (LXR) expression and activation. (A) RT-qPCR analysis of
LXRa and LXRb expression in aortic cells cultured for 3 days. Results are from a
single experiment with N = 3. (B) RT-qPCR analysis of ABCA1 expression (normal-
ized to b-actin) in wild-type (WT) and Lxrb/ cells treated for 10 days with vehicle
or T0901317 (5 lM). *P < 0.0001, **P < 0.005, NS – not signiﬁcant.
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2.1. Materials
Forskolin was from Calbiochem, T0901317 and Y27632 from
Cayman Chemical, and GW3965, 25-hydroxycholesterol (25-OH),
and phosphonoformic acid from Sigma–Aldrich.
2.2. Cell culture
Vascular cells (passages 4–8) were isolated from the thoracic
aorta of mice [25]. Lxrb/ mice were a gift of Dr. David Mangels-
dorf (UT Southwestern). The cells were immunoreactive for
smooth muscle a-actin, (Dako Corp.) but not for endothelial mark-
ers (von Willebrand factor, Dako Corp.). Cells were treated at con-
ﬂuence with the indicated reagents in a-minimal essential
medium (a-MEM) supplemented with 10% fetal bovine serum
and 5 mM b-glycerophosphate (Sigma). Media were replaced with
fresh agents every 3–4 days.
2.3. Mineral incorporation
Matrix calcium levels (normalized to total protein) were ana-
lyzed by the o-cresolphthalein complexone method (Teco Diagnos-
tics) in quintuplicate [21].
2.4. Alkaline phosphatase activity
ALP activity (normalized to total protein) was assessed colori-
metrically and assayed in quintuplicate [21].
2.5. Gene expression
Realtime RT-qPCR was performed using 1-step qRT-PCR (Bio-
chain Institute Inc.) in the Mx3005P (Stratagene). Primer sequences
are indicated previously [21], except for ABCA1 – (sense)
CGTGTGAGCAAAGCCAAG, (antisense) AAGATGATAATGACCAGTG-
TAGC; LXRa – (sense) TACAACCGGGAAGACTTTGC, (antisense)
TGCAGAGAAGATGCTGATGG; and LXRb – (sense) CAG-
GAGATTGTGGACTTTGC, (antisense) TTGTAGCGTCTGGCTGTTTC. b-
Actin was used as a normalizing gene.
2.6. Data analysis
Each experiment was performed in Ptriplicate wells and re-
peated Pthree times. Data are expressed as the means ± S.E.M.
Means were compared using one-way ANOVA, with comparison
of different groups by Fisher’s protected least signiﬁcant difference
test. A value of P 6 0.05 was considered signiﬁcant.
3. Results
3.1. LXR isotype expression
The level of LXRa expression is similar in aortic cells from WT
and Lxrb/ cells, whereas LXRb is reduced by 95% in the Lxrb/
cells (Fig. 1A). The residual Lxrb transcript detected in the Lxrb/
cells does not encode a functional protein (data not shown). Con-
sistent with this expression proﬁle, T0901317 upregulated expres-
sion of ABCA1, a known LXR target, by 10-fold in WT cells but only
2-fold in Lxrb/ cells (Fig. 1B).
3.2. Matrix mineralization
Treatment with the PKA activator forskolin (Fsk) for 10 days sig-
niﬁcantly increased matrix mineralization (Fig. 2A). T0901317alone had no signiﬁcant effect, whereas cotreatment with
T0901317 augmented Fsk-induced mineralization (Fig. 2A). This
effect was not observed in Lxrb/ cells (Fig. 2A). Other known
LXR agonists, GW3965 and 25-OH, also augmented the Fsk-in-
duced mineralization (Fig. 2A and B). Consistent with previous re-
sults [8], and in contrast to the synthetic LXR agonists, 25-OH alone
enhanced mineral incorporation, suggesting that 25-OH has effects
independent of LXR activation.
Next, we examined the effects of LXR agonists on regulators of
mineralization. Cotreatment with either T0901317 or GW3965
augmented the Fsk-induced ALP activity in WT (Fig. 2C) but not
in Lxrb/ cells (Fig. 2D). Treatment with Fsk for 6 h induced Pit-
1 mRNA in both WT and Lxrb/ cells (Fig. 3A). Cotreatment with
T0901317 signiﬁcantly augmented Fsk-induced Pit-1 expression
in WT, but not in Lxrb/ cells (Fig. 3A). At this time point,
T0901317 did not alter Fsk-induced expression of osteopontin
(OPN) and Enpp1 (Fig. 3B and C). However, longer (10 days)
T0901317 treatment attenuated Fsk-induced expression of both
Enpp1 and OPN in WT (Fig. 3B and C), but not in Lxrb/ cells (data
not shown), suggesting an indirect regulation by T0901317.
3.3. ALP and Pit-1 inhibition
To determine whether inhibition of ALP and Pit-1 attenuates the
effects of T0901317, we used their respective inhibitors, levamisole
(Lev) and phosphonoformic acid (PFA). Cotreatment with Lev
inhibited both Fsk- and Fsk/T0901317-induced matrix mineraliza-
tion (Fig. 4A). Similarly, cotreatment with PFA inhibited the effects
of T0901317 (Fig. 4B).
3.4. Intracellular signaling
An inhibitor of PKA, H89, was used to assess whether the effects
of T0901317 were upstream or downstream of PKA. In the pres-
Fig. 2. Matrix mineralization and alkaline phosphatase (ALP) activity. (A) Mineral
incorporation of cells treated for 10 days with vehicle, T0901317 (5 lM), GW3965
(2 lM) and/or Fsk (25 lM). (B) Mineral incorporation of cells treated for 15 days
with vehicle, 25-hydroxycholesterol (25-OH; 5 lM), and/or Fsk (25 lM). (C) ALP
activity of WT cells treated for 4 days with vehicle, T0901317 (5 lM) ± Fsk (25 lM).
(D) ALP activity of Lxrb/ cells treated for 4 days, as indicated in panel B.
*P < 0.0005, NS – not signiﬁcant.
Fig. 3. Gene expression. (A) RT-qPCR analysis of Pit-1 expression in WT or Lxrb/
cells treated for 6 h with vehicle, Fsk (10 lM) ± T0901317 (5 lM). *P < 0.001,
§P < 0.05. (B) RT-qPCR analysis of Enpp1 expression in wild-type (WT) cells treated
for 6 h or 10 days with vehicle, T0901317 (5 lM) ± Fsk (25 lM). *P < 0.0001,
P < 0.001. (C) RT-qPCR analysis of OPN in WT cells treated for 6 h or 10 days with
vehicle, T0901317 (5 lM) ± Fsk (25 lM). *P < 0.0001, P < 0.005.
Fig. 4. Inhibition of alkaline phosphatase (ALP) and Pit-1 activity. (A) Levamisol
(Lev). Mineral incorporation of wild-type (WT) cells treated for 10 days with
vehicle, Fsk (25 lM), Lev (0.1 mM), and/or T0901317 (5 lM). *P < 0.0001. (B)
Phosphonoformic acid (PFA). Mineral incorporation of WT cells treated for 10 days
with vehicle, Fsk (25 lM), PFA (0.5 mM), and/or T0901317 (5 lM). *P < 0.0001, NS –
not signiﬁcant.
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(Fig. 5A, compare Fsk + H89 to Fsk + T0 + H89), suggesting that
T0901317 acts downstream of PKA. Since Rho-associated
kinase (ROCK-II) has been shown to mediate the calcifying effects
of 7-ketocholesterol [7], we next examined its role in T0901317-in-
Fig. 5. Signaling pathways. (A) H89. Mineral incorporation of wild-type (WT) cells
treated for 10 days with vehicle, Fsk (25 lM), H89 (10 lM), and/or T0901317
(5 lM). *P < 0.0001. (B) Y27632. Mineral incorporation of WT cells treated for
10 days with vehicle, Fsk (25 lM), Y27632 (10 lM), and/or T0901317 (5 lM).
*P < 0.0001, **P = 0.001, NS – not signiﬁcant. (C) Schematic model of possible
mechanisms of effects of liver X receptor agonist, T0901317, on Fsk-induced
mineralization.
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ited Fsk-induced calciﬁcation and completely attenuated Fsk/
T0901317-induced mineralization (Fig. 5B).4. Discussion
Given that LXR agonists have anti-atherogenic effects and that
calciﬁcation is highly prevalent in atherosclerotic plaques, we
investigated the effects of synthetic LXR agonists on vascular cell
mineralization using synthetic LXR agonists in aortic cells isolated
from WT and Lxrb/mice. Results showed that although LXR ago-
nists alone had no signiﬁcant effect, they augmented PKA-induced
mineralization in WT cells. The effect appears to be LXRb-depen-
dent, since it is not seen in Lxrb/ cells.
Results suggest that LXR agonists augmented Fsk-induced min-
eralization by enhancing positive regulators of mineralization,
such as ALP activity and, possibly, Pit-1 and/or by attenuating
inhibitors of mineralization, OPN and Enpp1, as depicted in
Fig. 5C. Interestingly, the role of Enpp1 is complex since excess
Enpp1 can also promote calciﬁcation by providing a substrate for
ALP [26]. Indeed, this may explain how Fsk can induce calciﬁcation
despite its induction of Enpp1. Short-term regulation of Pit-1
induction by T0901317 suggests a direct, genomic effect of LXR,
whereas inhibition of OPN and Enpp1 required longer treatment,
suggesting an indirect mechanism. Results also suggest that
T0901317 action occurs downstream of PKA and may be mediatedby ROCK-II, which regulates myoﬁbroblast differentiation, extra-
cellular matrix production [27] and matrix mineralization induced
by 7-ketocholesterol [7]. ROCK-II also appears to contribute to
PKA-mediated calciﬁcation itself since Fsk-induced mineralization
was partially blocked by Y27632.
Evidence suggests that high phosphate levels induce matrix
mineralization by vascular smooth muscle cells via Pit-1
[17,28]. Pit-1 is also a downstream effector for other mineraliza-
tion factors, including BMP-2 [29]. In the present study, Fsk-in-
duced Pit-1 expression was augmented by short-term treatment
with T0901317, suggesting transcriptional regulation. Indeed,
two putative LXR response elements are located in the promoter
region of Pit-1, and studies of their functional role are underway.
In our results, the attenuation of matrix mineralization by PFA,
which inhibits Pit-1 [29–31], suggests a role of Pit-1 induction
in effects of LXR agonists. However, since PFA is also a PPi ana-
log, it is also possible that PFA inhibition is through this alterna-
tive mechanism rather than through Pit-1. Further studies are
required to discern whether Pit-1 has a role in the LXR agonist
effects.
Chronic inﬂammation, responsible for atherogenesis, also in-
duces vascular cell calciﬁcation [11–13], suggesting that similar
pathways may regulate both pathogenic processes. Since LXR acti-
vation attenuates inﬂammation, it is less likely that LXR poses ad-
verse effects in arteries lacking atherosclerosis. However, our
ﬁndings suggest that LXR activation could adversely affect arteries
exposed to other pathological factors such as high phosphate and
increased PTH signaling seen in end-stage renal patients with
hyperparathyroidism.
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